# Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

> **NCT01879020** · PHASE1 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 61 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** TA-8995
- **DRUG:** TA-8995
- **DRUG:** TA-8995
- **DRUG:** TA-8995
- **DRUG:** TA-8995
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01879020
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2013-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01879020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01879020, "Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01879020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*